After bumper 2024, Futura warns of lower 2025 sales on slow US uptake

(Alliance News) - Futura Medical PLC on Friday said it expects 2024 revenue and post-tax profit ...

Alliance News 31 January, 2025 | 11:39AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Futura Medical PLC on Friday said it expects 2024 revenue and post-tax profit ahead of guidance, but warned of 2025 sales below market expectations, due to slow uptake in the US of its erectile dysfunction treatment.

The Guildford, Surrey-based sexual health products company estimated 2024 revenue of at least GBP13.7 million, multiplied from GBP3.1 million in 2023. Post-tax profit is expected to exceed market forecasts, which Futura cited as GBP500,000.

However, the company cautioned that 2025 revenue and profits will be "materially below" current market expectations, due to the pace of US consumer uptake of Eroxon, Futura's erectile dysfunction treatment.

The company now expects to make a loss in 2025, compared to previous market expectations of a GBP6.3 million post-tax profit on revenue of GBP18.5 million.

Futura launched Eroxon in the US in October 2024 through its commercial partner Haleon PLC, triggering a USD5 million payment. While early retailer uptake and launch execution were strong, barriers to purchase - such as lockboxes in stores that require staff assistance - have hurt sales.

Futura said Haleon is adjusting its marketing approach to include targeted TV campaigns, in an effort to boost sales.

Chief Executive James Barder said: "Whilst it has been slower than anticipated to generate consumer awareness, and resulting sales, in a completely new product in a new consumer market that naturally has some stigma attached to it, we, and our partners, remain confident in the future prospects for Eroxon."

Eroxon is now available in 15 countries across the Americas, Middle East, and Europe, with plans to expand to 20 countries by the end of 2025.

Beyond Eroxon, Futura is advancing Eroxon Intense, a stronger-sensation variant, expected to receive marketing authorisation by the end of 2025.

Futura said its balance sheet remains "robust", with GBP6.6 million in cash as of December 31, providing working capital through to the second half of 2026.

Futura expects to report its full-year results in April 2025.

Shares in Futura Medical were up 3.0% at 17.00 pence in London on Friday morning.

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Futura Medical PLC 16.94 GBX 2.67 -
Haleon PLC 371.40 GBX -1.14

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures